Authors

Latest:

Ashani Weeraratna on Aging and Melanoma

Ashani Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, member, The Wistar Institute Melanoma Research Center, discusses a study examining the effects of aging on Wnt/ÃŸ-catenin signaling in melanoma.

Asher A. Chanan-Khan, MD

Latest:

Dr. Chanan-Khan on Ibrutinib as Backbone of Treatment for CLL

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).

Ashish M. Kamat, MD

Latest:

Dr. Kamat on the Process of Meeting BCG Needs in Bladder Cancer

Ashish M. Kamat, MD, discusses the process of meeting the needs for TICE Bacillus Calmette–Guérin in the treatment of patients with bladder cancer.

Ashish Saxena, MD, PhD, Weill Cornell Medical College

Latest:

Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLC

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

Ashkan Malayeri, MD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Ashley A. Weiner, MD, PhD

Latest:

Dr. Weiner on Radiotherapy Trials in NSCLC

Ashley A. Weiner, MD, PhD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses clinical trials that have investigated the use of radiotherapy in patients with non–small cell lung cancer (NSCLC).

Ashley E. Ross, MD, PhD, Johns Hopkins Medical Institution

Ashley Rosko, MD

Latest:

Dr. Rosko on Disparities Within Clinical Trials in Multiple Myeloma

Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.

Asif Ahmad

Latest:

Innovation in EHR Technology Drives Quality Oncology Care

The mantra in oncology over the last several years has revolved around how practices should deal with the myriad of challenges they face: new guidelines and regulations, lower reimbursement and a shift toward value-based patient care.

Asim Amin, MD, PhD

Latest:

Dr. Amin on CheckMate-214 Trial in RCC

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses the rationale for the pivotal CheckMate-214 trial in advanced renal cell carcinoma.

Asma Dilawari, MD

Latest:

It's Time to Integrate Complementary Medicine Discussions Into Oncology Care

The goal of increasing communications with the patient about all available and useful therapies contributes to better care of individuals and allows for continued education from oncology providers on potential risks and benefits of such therapies.

Assuntina G. Sacco, MD

Latest:

Dr. Sacco on Ongoing Trials for Chemoradiation in Head and Neck Cancer

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses ongoing trials investigating chemoradiation for patients with head and neck cancer.

Atif Hussein, MD

Latest:

Dr. Hussein on the Evolution of Treatment in HCC

Atif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.

Atish D. Choudhury, MD, PhD

Latest:

Dr Choudhury on Survival Advantages With AR Pathway Inhibitors in mHSPC

Atish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.

Audrey Andrews

Latest:

ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

The novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.

Audrey Sternberg

Latest:

Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCC

The addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.

Augusto Villanueva, MD

Latest:

Dr. Villanueva on Eliminating Tumor Heterogeneity in Patients With HCC

Augusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.

Augusto Villanueva, MD, PhD

Latest:

Dr. Villanueva on Challenges For Liquid Biopsies in HCC

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses remaining challenges with liquid biopsies in hepatocellular carcinoma.

Austin Dosch, MD

Latest:

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Avital Harari, MD

Latest:

Researchers Investigate Increased Incidence of Thyroid Cancer in California

To investigate the possibility of environmental impacts as a predisposition for thyroid cancer, researchers sought to identify counties in California with possible geographic clustering of advanced thyroid cancer cases.